2021 was a historic year in the battle to defeat cancer.
More novel cancer treatments became available than ever before with the number of Oncology specific clinical trials also reaching an all-time high, up 56% from 2016 and mostly focused on rare cancer indications.
With global spending on Oncology expected to exceed $300
It should come as little surprise that the rise in decentralized trials (DCTs) and increase in study complexities have magnified performance demands across clinical trial teams.
A recent survey by Ernst & Young found 50% of clinical trials will be hybrid or decentralized by 2024. This is welcome news for sponsors
Atul Mahableshwarkar, M.D., DFAPA, joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss clinical trial methodology. A self-described “trial nerd,” Atul illuminates the make-or-break role methodology plays in a trial’s success and shares his advice and best practices for making positive outcomes possible.
Enjoy this interview
The area of clinical research known as CNS (central nervous system conditions) is commonly cited for its complexity and the subjective nature of many assessment tools. CNS clinicians therefore must commit to tackling unique challenges affecting their patients and the research they conduct.
It should be no surprise that the life
Jennifer Brandl joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss the feasibility and pros and cons of virtual site initiation visits. A clinical operations expert with a passion for data science, Jennifer shares her experience transitioning from pre-clinical to clinical research and her confidence
It’s impossible to read an industry publication without hearing about virtual clinical trials, decentralized clinical trials, or hybrid trials. Industry leaders and technology companies are touting the advantages and the opportunities to anyone who will listen. You may understand the model, and you may recognize the effort to shift. But
Peju Oshisanya joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss diversity and inclusion in clinical trials. An experienced clinical operations specialist and a strong advocate for data diversity, Peju shares her insight into the health sciences industry, evaluates opportunities for improvement, and illuminates the
If it shocks you to hear that clinical trials are getting more complex, you haven’t been paying attention. Specifically, we’re collecting more endpoints. We’re performing more procedures. We’re increasing nearly every executional variable, like the number of countries, the number of sites, the number of visits per patient, and the